ArticleDiabetes, obesity & metabolism2026
Modelling the Clinical and Complication-Related Economic Burden of Therapeutic Inertia in People With Type 2 Diabetes in China.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modelling the Clinical and Complication-Related Economic Burden of Therapeutic Inertia in People With Type 2 Diabetes in China.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimTo quantify the long-term clinical and complication-related economic burden of therapeutic inertia in type 2 diabetes mellitus (T2DM) in China, focusing on delayed insulin initiation and intensification.
methodsA health economic analysis was conducted from the perspective of the Chinese healthcare system using the validated CORE Diabetes Model. Two cohorts were simulated to compare timely versus delayed insulin initiation and intensification. Base-case assumptions included a baseline HbA1c of 9.0%, a 5-year treatment delay and a 30-year time horizon. Model inputs, including patient characteristics, treatment effects, costs and utilities, were sourced from published literature, prioritising Chinese data. Outcomes included quality-adjusted life years (QALYs), complication incidence and complication-related direct medical costs, with scenario analyses performed to test robustness. Results were also extrapolated to the national population of Chinese patients with uncontrolled T2DM.
resultsTimely insulin initiation was associated with an average saving of ¥11 370 per patient and a gain of 0.086 QALYs compared with a 5-year delay. Timely intensification yielded cost savings of ¥10 417 and an incremental 0.093 QALYs per patient. At the population level, these corresponded to total savings of ¥68.2 billion and ¥62.5 billion, and additional 515 604 and 557 572 QALYs, respectively. Scenario analyses confirmed that health and cost benefits increased with higher baseline HbA1c and longer time horizons.
conclusionsTherapeutic inertia in T2DM management imposes quantifiable QALY losses and complication-related cost burdens in China. Timely insulin initiation and intensification significantly improve outcomes and reduce costs, underscoring the urgency of overcoming therapeutic inertia through patient, physician and system-level strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.